{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:01:40Z","timestamp":1789441300089,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in both newly diagnosed and relapsing patients. However, the role of RTX in the management of the most severe cases of AAV remains to be fully elucidated. The aim of this study was to assess both safety and efficacy of an intensified B-cell depletion therapy (IBCDT) protocol, including RTX, cyclophosphamide (CYC), and methylprednisolone pulses without additional maintenance immunosuppressive therapy in a cohort of 15 AAV patients with the most severe features of AVV renal involvement (as &amp;lt;15 ml\/min GFR and histological findings of paucimmune necrotizing glomerulonephritis with more than 50% crescents of non-sclerotic glomeruli at the renal biopsy). Results of the IBCDT regimen have been compared to those obtained in a control cohort of 10 patients with AAV treated with a conventional therapy regimen based on oral CYC and steroids followed by a prolonged maintenance therapy with azathioprine (AZA). Plasma exchange was equally employed in the study and the control group. Complete clinical remission (BVAS 0) was observed at 6 months in 14 of 15 patients treated with IBCDT (93%). All cases who achieved a complete clinical remission experienced a depletion of peripheral blood B cells at the end of therapy. Of the 10 dialysis dependent patients at onset, 6 subjects (60%) experienced a functional recovery allowing the suspension of dialysis treatment. When compared to the control group, no statistically significant difference was observed in patients treated with IBCDT in terms of overall survival, 6-month therapeutic response rate, and 6-, and 12-month functional renal recovery. The cumulative total dose of CYC in the case group was on average 1 g\/patient while in the control group on average 8.5 g\/patient (p = 0.00008). Despite the retrospective design and relative limited sample size, IBCDT appeared to be safe and had the same efficacy profile when compared to the conventional therapy with CYC plus AZA in the management of the most severe patients with AAV. Additionally, this avoided the need of prolonged maintenance therapy for long, and limited the exposure to CYC with consequent reduced toxicity and drug-related side effect rates.<\/jats:p>","DOI":"10.3389\/fimmu.2022.777134","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T06:30:14Z","timestamp":1648535414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Murgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Quattrocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Naretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Barreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sammartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of Systemic Vasculitides. Proposal of an International Consensus Conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054593","article-title":"Development and Validation of a Consensus Methodology for the Classification of the ANCA-Associated Vasculitides and Polyarteritis Nodosa for Epidemiological Studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically Distinct Subsets Within ANCA-Associated Vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.34590","article-title":"How can We Predict the Risk of Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis? Comment on the Article by Walsh et al","volume":"64","author":"Sch\u00f6nermarck","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the Anca-Associated Vasculitides: Long-Term Data From the European Vasculitis Study Group (EUVAS) Therapeutic Trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab Versus Cyclophosphamide in ANCA-Associated Renal Vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-Term Follow-Up of Patients Who Received Repeat-Dose Rituximab as Maintenance Therapy for ANCA-Associated Vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.34583","article-title":"Rituximab for Remission Maintenance in Relapsing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for Induction and Maintenance Treatment of ANCA-Associated Vasculitides: A Multicentre Retrospective Study on 80 Patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07340713","article-title":"Long-Term Maintenance Therapy Using Rituximab-Induced Continuous B-Cell Depletion in Patients With ANCA Vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7326\/L20-1199","article-title":"Long-Term Rituximab Useto Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr109","article-title":"Intensive Short-Term Treatment With Rituximab,Cyclophosphamide and Methylprednisolone Pulses Induces Remission in Severe Casesof SLE With Nephritis and Avoids Further Immunosuppressive Maintenance Therapy","volume":"26","author":"Roccatello","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A 4-Year Observation in Lupus Nephritis Patients Treated With an Intensified B-Lymphocyte Depletion Without Immunosoppressive Maintenance Treatment-Clinical Response Compared to Literature and Immunological Re-Assessment","volume":"14","author":"Roccatello","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/jcm10020292","article-title":"A 3-Year Observational Study of Patients Withprogressive Systemic Sclerosis Treated With an Intensified B LymphocyteDepletion Protocol: Clinical and Immunological Response","volume":"10","author":"Rossi","year":"2021","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.01.027","article-title":"A Prospective Study on Long-TermClinical Outcomes of Patients With Lupus Nephritis Treated With an IntensifiedB-Cell Depletion Protocol Without Maintenance Therapy","volume":"6","author":"Roccatello","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR Using the CKD Epidemiology Collaboration(CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalenceestimates, and Better Risk Predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and Validation of the Birmingham Vasculitis ActivityScore (Version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of Rituximab and Plasma Exchange Inantineutrophil Cytoplasmic Antibody-Associated Vasculitis With Severe KidneyDisease","volume":"31","author":"Casal Moura","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000329535","article-title":"Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients With Vasculitis","volume":"34","author":"Roccatello","year":"2011","journal-title":"Am J Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapyfor Severe Renal Vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000431336","article-title":"Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis With Rituximab","volume":"41","author":"Shah","year":"2015","journal-title":"Am J Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab Versus Cyclophosphamide for ANCA Associated Vasculitis With Renal Involvement","volume":"26","author":"Duvuru","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803175","article-title":"A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis","author":"Arnold","year":"2021","journal-title":"EULAR"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse Versus Daily Oralcyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmicantibody-Associated Vasculitis: A Randomized Trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu042","article-title":"Repeat Protocol Renal Biopsy in ANCA-Associated Renal Vasculitis","volume":"29","author":"Hruskova","year":"2014","journal-title":"Nephrol Dialysis Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.777134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T06:30:15Z","timestamp":1648535415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.777134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2022.777134"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.777134","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"article-number":"777134"}}